Serum concentrations of laminin-P1 in thrombotic microangiopathy: usefulness as an index of activity and prognostic value.
Laminin is the main noncollagenous constituent of the basement membrane, and its serum levels could reflect the metabolic changes that occur in the basement membrane. Severe endothelial injury with thickening of basement membrane is a characteristic feature of thrombotic microangiopathy (TMA). With this background, the aim of the study was to investigate in a prospective way (1) the relationship among serum Lam-P1, the extent of renal histopathologic lesions, and the biochemical parameters commonly used as markers of TMA activity, and (2) the usefulness of serum Lam-P1 concentrations as a renal outcome prognostic index. To this end, 18 consecutive patients with active biopsy-proven TMA with renal involvement were studied. One hundred and twenty-one healthy control subjects, 20 patients with systemic scleroderma without renal involvement, and 35 patients with systemic lupus erythematosus (20 without nephropathy and 15 with diffuse proliferative type 4 lupus nephritis) were used as control groups. In addition, to analyze the influence of either renal failure or hemodialysis therapy on serum Lam-P1 levels, 91 patients on regular hemodialysis therapy and 81 patients with predialysis chronic renal failure of different etiologies were included in the study. Serum Lam-P1 was determined by RIA at admission, on days 10 and 30 of follow-up in all patients, and after 6 and 12 mo of follow-up in all surviving patients. Serum lactate dehydrogenase, haptoglobin, platelet count, hemoglobin, and serum creatinine were determined as markers of endothelial dysfunction and hemolysis. At admission, serum levels of Lam-P1 were significantly higher in patients with TMA than in healthy control subjects (3.39 +/- 0.56 U/ml versus 1.40 +/- 0.18 U/ml; P < 0.0001). In addition, patients with TMA had significantly higher serum Lam-P1 levels than the other groups included in the study. At the first control, Lam-P1 correlated with lactate dehydrogenase (P = 0.006) and hemoglobin (P = 0.002). During follow-up, platelet count and hemolysis indicators normalized in all patients, while serum Lam-P1 decreased only in patients with renal function recovery. In multivariate analysis, serum creatinine and Lam-P1 at day 10 were the only independent predictors of renal outcome (r2 = 0.94; P < 0.0001) and also correlated with indices of histopathologic damage (P < 0.001). Serum Lam-P1 normalized in all patients with chronic renal failure in the samples obtained at 6 and 12 mo of regular hemodialysis after solving active TMA, thus suggesting that histopathologic lesions, but not renal function itself, would be mainly responsible for the high Lam-P1 serum concentrations detected in TMA. In conclusion, serum Lam-P1 concentrations are increased in patients with active TMA. Furthermore, patients with poor renal outcome show a prolonged increase of serum Lam-P1 that is related to the extent of renal histologic lesions. Unlike the biochemical markers of hemolysis commonly used to assess TMA activity, the sequential determination of serum Lam-P1 provides valuable information about long-term renal prognosis in patients with TMA.
Segarra
Alfons
A
Department of Nephrology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Simó
Rafael
R
Department of Endocrinology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Masmiquel
Lluis
L
Department of Endocrinology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Segura
Rosa M
RM
Department of Biochemistry, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Fonollosa
Vicens
V
Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Huguet
Pere
P
Department of Pathology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Majo
Joaquim
J
Department of Pathology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Piera
Lluis
L
Department of Nephrology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Schwartz
Simó
S
Biochemistry and Molecular Biology Research Center, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
D000328:Adult; D015415:Biomarkers / Q000097:blood; D006801:Humans; D007668:Kidney / Q000473:pathology; D007797:Laminin / Q000097:blood*; D008833:Microcirculation; D008875:Middle Aged; D009994:Osmolar Concentration; D010446:Peptide Fragments / Q000097:blood*; D011379:Prognosis; D011446:Prospective Studies; D013927:Thrombosis / Q000097:blood* / Q000473:pathology
D015415:Biomarkers; D007797:Laminin; D010446:Peptide Fragments; C055716:laminin P1